Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on January 9, 2017, to announce its key business priorities for 2017 and provide preliminary financial information for the fourth quarter and full year ended December 31, 2016. The filing incorporates by reference a press release dated January 8, 2016, which contains these preliminary results and future outlook. Investors should note that the information in the press release is furnished and not deemed "filed" for purposes of liability under Section 18 of the Securities Exchange Act of 1934.
Key Highlights
- 1Vertex announced its key business priorities for 2017.
- 2Preliminary revenue and other financial information for Q4 and Full Year 2016 was provided.
- 3The filing references a press release dated January 8, 2016, containing the details of the announcement.
- 4The press release information is furnished, not filed, meaning it does not carry the same liability under Section 18 of the Exchange Act.
- 5This 8-K serves to officially incorporate the press release into the company's SEC filings.
- 6Investors are directed to Exhibit 99.1 for the specific preliminary financial figures and business priorities.